Granite Point Capital founder, CEO, and chief investment officer Warren Lammert co-founded the community website Epilepsy.com and the nonprofit Epilepsy Therapy Project in the early 2000s after discovering that his daughter was living with a rare epileptic disorder known as Dravet syndrome. While the Epilepsy Therapy Project merged with the Epilepsy Foundation in 2013, Warren Lammert continues to pursue a cure for rare epileptic disorders through his entrepreneurial endeavors and involvement in the biomedical research sector.
In this regard, Warren Lammert serves as the chairman of the board of directors of Tevard Biosciences, a gene-therapy firm in Cambridge, Massachusetts, that he co-founded in 2017. He further engages in epilepsy research in his capacity as the chairman of the board of Colorado-based Cerebral Therapeutics, a clinical-stage pharmaceutical company focused on neurologically based illnesses. Mr. Lammert also serves on the board of directors of Engage Therapeutics, which developed Staccato Alprazolam, a handheld drug device that is being tested for use as a method of treating individual epileptic seizures as they occur.
Warren Lammert has been quoted on epilepsy research-related subjects on CBS Denver and MSNBC, as well as in The New York Times. Due to his longtime dedication to the cause, he was honored in 2007 by the NYU group Finding a Cure for Epilepsy and Seizures (FACES). Mr. Lammert’s work also earned him recognition as an honoree at the Epilepsy Foundation 2013 World Changers: Art of Innovation Gala and as a recipient of the Epilepsy New England Lifetime Achievement Award.
